ASCO Recommends Against Routine Adjuvant Chemo For Stage II Colon Cancer
Exercise Improves Function, Symptoms Of Cancer Survivors, AHRQ Report Finds
Guideline Adherence Improves Early Breast Cancer Survival
Chemosensitivity, Resistance Assays Not Ready For Clinic, ASCO Tech Assessment Says
FDA Approves Taxotere For Node+ Breast Cancer
FDA Approves Lilly’s Alimta For Metastatic NSCLC
Reduced Risk of Metastasis When Screening Finds Cancer
Ellence Has Lower Risk Of Heart Damage, Study Finds
Modality Combo Decreases Prostate Cancer Recurrence
Hormonal Therapy Improves Prostate Cancer Survival
Study Suggests Surveillance Colonoscopies Overperformed
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer
